Skip to content

8-KAccepted Aug 3, 4:10 PM ET

Oric Pharmaceuticals Reports Results for Quarter Ended June 30, 2026

ORICOric Pharmaceuticals, Inc.

Accepted (ET)

4:10 PM

Aug 3, 2026

Filed

Aug 3, 2026

Documents

11

Size

424.0 KB

Summary

Oric Pharmaceuticals Reports Results for Quarter Ended June 30, 2026

Updated

What Happened
Oric Pharmaceuticals, Inc. announced its financial results for the fiscal quarter ended June 30, 2026 by issuing a press release on August 3, 2026. The press release was furnished with the SEC on Form 8-K as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).

Key Details

  • Filing date: August 3, 2026.
  • Reporting period: fiscal quarter ended June 30, 2026.
  • Press release attached as Exhibit 99.1 to the 8-K and incorporated by reference into the filing.
  • Per Item 9.01, the furnished press release is expressly noted as “furnished” (not “filed”) and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other filings.

Why It Matters
This 8-K provides investors with Oric’s latest quarterly results and an official company summary of its financial condition for the period ending June 30, 2026. Investors should review Exhibit 99.1 (the press release) for the specific numbers—revenue, earnings (loss), cash position, and any management commentary—because those details can affect valuation and near‑term trading. Note also the legal distinction that the information was furnished rather than filed, which limits statutory liability and how the content may be used in future SEC filings.

AI-written summary · check the filing